As of March 31, 2025, the company had cash and cash equivalents of $13.9 million, compared to $23.3 million as of December 31, 2024. The company believes its cash balance as of March 31, 2025, is adequate to fund its basic budgeted operations into the fourth quarter of 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- CLRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cellectar Biosciences announces plan to explore strategic alternatives
- Cellectar Biosciences Enhances CEO and COO Severance Benefits
- Cellectar Biosciences: Promising Future with FDA Clarity and Innovative Radiopharmaceutical Advancements
- Cellectar Biosciences Faces Financial and Legal Turmoil Amidst Restated Earnings
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue